Is there an antiandrogen withdrawal syndrome with enzalutamide?

BJU International

Volumn 115, Issue 3, 2015, Pages 373-380

  Rodriguez Vida, Alejo ^a   Bianchini, Diletta ^b   Van Hemelrijck, Mieke ^c   Hughes, Simon ^a   Malik, Zafar ^d   Powles, Thomas ^e   Bahl, Amit ^f   Rudman, Sarah ^a   Payne, Heather ^g   De Bono, Johann ^b   Chowdhury, Simon ^a  

^a GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

^d CLATTERBRIDGE CENTRE FOR ONCOLOGY   (United Kingdom)

^e ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

^f UNIVERSITY HOSPITALS BRISTOL NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

Author keywords

androgen receptor gene F876L mutation; androgen receptor targeting; antiandrogen withdrawal syndrome; castration resistant prostate cancer; enzalutamide; hormone therapy

Indexed keywords

ABIRATERONE; CABAZITAXEL; DOCETAXEL; ENZALUTAMIDE; PROSTATE SPECIFIC ANTIGEN; ANTIANDROGEN; ANTINEOPLASTIC AGENT; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PHENYLTHIOHYDANTOIN;

ADULT; AGED; ANTIANDROGEN THERAPY; ARTICLE; BONE METASTASIS; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; DRUG RESPONSE; DRUG WITHDRAWAL; HUMAN; LYMPH NODE METASTASIS; MALE; MIDDLE AGED; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME; ANALOGS AND DERIVATIVES; BLOOD; KAPLAN MEIER METHOD; PATHOLOGY; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; SUBSTANCE WITHDRAWAL SYNDROME; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS; HUMANS; KALLIKREINS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENYLTHIOHYDANTOIN; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RETROSPECTIVE STUDIES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 84922864661     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12826     Document Type: Article

References (27)

1. Bray F, Lortet-Tieulent J, Ferlay J, et al. Prostate cancer incidence and mortality trends in 37 European countries: an overview. Eur J Cancer 2010; 46: 3040-3052
2. Crawford ED, Eisenberger MA, McLeod DG, et al. A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 1989; 321: 419-424. [Erratum, N Engl J Med 1989;321:1420.]
3. Eisenberger MA, Blumenstein BA, Crawford ED, et al. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer. N Engl J Med 1998; 339: 1036-1042
4. Sartor AO, Tangen CM, Hussain MH, et al. Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426). Cancer 2008; 112: 2393-2400
5. Small EJ, Halabi S, Dawson NA, et al. Antiandrogen withdrawal alone or in combination with ketoconazole in androgen-independent prostate cancer patients: a phase III trial (CALGB 9583). J Clin Oncol 2004; 22: 1025-1033
6. Schellhammer PF, Venner P, Haas GP, et al. Prostate specific antigen decreases after withdrawal of antiandrogen therapy with bicalutamide or flutamide in patients receiving combined androgen blockade. J Urol 1997; 157: 1731-1735
7. Scher HI, Kelly WK,. Prostate specific antigen decline after antiandrogen withdrawal: the flutamide withdrawal syndrome. J Urol 1993; 149: 607-609
8. Dupont A, Gomez JL, Cusan L, et al. Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 1993; 150: 908-913
9. Small EJ, Carroll PR,. Prostate-specific antigen decline after casodex withdrawal: evidence for an antiandrogen withdrawal syndrome. Urology 1994; 43: 408-410
10. Gomella LG, Ismail M, Nathan FE,. Antiandrogen withdrawal syndrome with nilutamide. J Urol 1997; 157: 1366
11. Huan SD, Gerridzen RG, Yau JC, Stewart DJ,. Antiandrogen withdrawal syndrome with nilutamide. Urology 1997; 49: 632-634
12. Sella A, Flex D, Sulkes A, Baniel J,. Antiandrogen withdrawal syndrome with cyproterone acetate. Urology 1998; 52: 1091-1093
13. Dawson NA, McLeod DG,. Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: expansion of the antiandrogen withdrawal syndrome. J Urol 1995; 153: 1946-1947
14. Sartor O, Eastham JA,. Progressive prostate cancer associated with use of megestrol acetate administered for control of hot flashes. South Med J 1999; 92: 415-416
15. Miyamoto H, Rahman MM, Chang C,. Molecular basis for the antiandrogen withdrawal syndrome. J Cell Biochem 2004; 91: 3-12. [Review]
16. Hara T, Miyazaki J, Araki H, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res 2003; 63: 149-153
17. Veldscholte J, Berrevoets CA, Brinkmann AO, Grootegoed JA, Mulder E,. Anti-androgens and the mutated androgen receptor of LNCaP cells: differential effects on binding affinity, heat-shock protein interaction, and transcription activation. Biochemistry 1992; 31: 2393-2399
18. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367: 1187-1197
19. Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science 2009; 324: 787-790
20. Scher HI, Halabi S, Tannock I, et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 2008; 26: 1148-1159
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-247
22. Drug Bank. Available at: http://www.drugbank.ca/drugs/DB01128. Accessed August 2014
23. Drug Bank. Available at: http://www.drugbank.ca/drugs/DB00499. Accessed August 2014
24. Drug Bank. Available at: http://www.drugbank.ca/drugs/DB08899. Accessed August 2014
25. Balbas MD, Evans MJ, Hosfield DJ, et al. Overcoming mutation-based resistance to antiandrogens with rational drug design. Elife 2013; 2: e00499
26. Joseph JD, Lu N, Qian J, et al. A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509. Cancer Discov 2013; 3: 1020-1029
27. Korpal M, Korn JM, Gao X, et al. An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (Enzalutamide). Cancer Discov 2013; 3: 1030-1043